Clinical pharmacology of lasofoxifene in Japanese and white postmenopausal women

Journal of Clinical Pharmacology

Volumn 46, Issue 6, 2006, Pages 693-699

  Fountaine, R J ^a   Nishizawa, Y ^b   Wei, G ^b   Dogolo, L ^b   Calcagni, A ^b   Gardner, M J ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

Ethnicity; Lasofoxifene; Menopause; Pharmacokinetics; SERM

Indexed keywords

LASOFOXIFENE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN EXPERIMENT; JAPAN; NORMAL HUMAN; POSTMENOPAUSE; SIDE EFFECT;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; AMINO ACIDS; ASIAN CONTINENTAL ANCESTRY GROUP; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; MIDDLE AGED; PEPTIDES; POSTMENOPAUSE; PYRROLIDINES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TETRAHYDRONAPHTHALENES;

EID: 33745286232     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006288213     Document Type: Article

References (24)

1. International Osteoporosis Foundation. Facts and statistics about osteoporosis and its impact. International Osteoporosis Foundation Web site. Available at: www.osteofound.org/press_centre/fact_sheet.html. Accessed January 4, 2006.
2. Eppenberger U, Wosikowski K, Kung W. Pharmacologic and biological properties of droloxifene, a new antiestrogen. Am J Clin Oncol. 1991;14(suppl 2):S5-S14.
3. Bryant HU, Glasebrook AL, Yang NN, Sato M. A pharmacological review of raloxifene. J Bone Miner Metab. 1996;14:1-9.
4. Key TJ, Chen J, Wang DY, Pike MC, Boreham J. Sex hormones in women in rural China and in Britain. Br J Cancer. 1990;62:631-636.
5. Adlercreutz H, Gorbach SL, Goldin BR, Woods MN, Dwyer JT, Hämäläinen E. Estrogen metabolism and excretion in Oriental and Caucasian women. J Natl Cancer Inst. 1994;86:1076-1082.
6. Martucci CP, Fishman J. P450 enzymes of estrogen metabolism. Pharmacol Ther. 1993;57:237-257.
7. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815-850.
8. Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev. 2003;35:99-106.
9. Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther. 2001;299:825-831.
10. Hochner-Celnikier D. Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gynaecol Reprod Biol. 1999;85:23-29.
11. Johnson KA, Gardner MJ, Prakash C. In vivo and in vitro metabolism of a next-generation selective estrogen receptor modulator, lasofoxifene, in humans. Drug Metab Rev. 2004;36(S1):246.
12. Bramson C, Ouellet D, Roman D, Randinitis E, Gardner M. A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment. J Clin Pharmacol. 2006;46:29-36.
13. Morello KC, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet. 2003;42:361-372.
14. Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the antiestrogen tamoxifen on cardiovascular factors in normal postmenopausal women. J Clin Endocrinol Metab. 1995;80:3191-3195.
15. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Metab. 1996;11:835-842.
16. Ke HZ, Paralkar VM, Grasser WA, et al. Effects of CP-336,156, a new nonsteroidal estrogen agonist-antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology. 1998;139:2068-2076.
17. Ke HZ, Foley GL, Simmons HA, Shen V, Thompson DD. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology. 2004;145:1996-2005.
18. McClung M, Omizo M, Weiss S, et al. Comparison of lasofoxifene and raloxifene for the prevention of bone loss in postmenopausal women. J Bone Miner Res. 2004;19(suppl 1):S96.
19. Rosati RL, Da Silva Jardine P, Cameron KO, et al. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem. 1998;41:2928-2931.
20. Tanaka Y, Sekiguchi M, Sawamoto T, et al. Pharmacokinetics of droloxifene in mice, rats, monkeys, premenopausal and postmenopausal patients. Eur J Drug Metab Pharmacokinet. 1994;19:47-58.
21. Ettinger M, Schwartz E, Emkey R, et al. Lasofoxifene: a next generation selective estrogen receptor modulator (SERM), in the prevention of bone loss in postmenopausal women. Presented at: ENDO 2004; June 16-19, 2004; New Orleans, La. Abstract S35-2.
22. Bolognese M, Weiss SR, Ettinger MP, Moffett AH, Lee A. Lasofoxifene: a next generation selective estrogen receptor modulator (SERM) for the prevention of bone loss in postmenopausal women. Osteoporos Int. 2004;15(suppl 1):S11.
23. Moller R, Fisher J, Taylor A, Kolluri S, Gardner. The effects of lasofoxifene on the single dose pharmacokinetics of chlorzoxazone and dextromethorphan in postmenopausal women. AAPS J. 2004;6(S1):R6215.
24. Bolognese M, Moffett A, Lee A, et al. Lasofoxifene is superior to raloxifene in the prevention of bone loss in postmenopausal women: 1-year results. Bone. 2003;32(suppl 5):S93.